

**CAUTIONS, FURTHER INFORMATION** Rarely, the varicella-zoster vaccine virus has been transmitted from the vaccinated individual to close contacts. Therefore, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4–6 weeks of the first or second dose:

- varicella-susceptible pregnant women;
- individuals at high risk of severe varicella, including those with immunodeficiency or those receiving immunosuppressive therapy.

Healthcare workers who develop a generalised papular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted. Those who develop a localised rash after vaccination should cover the lesions and be allowed to continue working unless in contact with patients at high risk of severe varicella.

- ▶ Administration with MMR vaccine Varicella-zoster and MMR vaccines can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.

- **INTERACTIONS** → Appendix 1: live vaccines
- **SIDE-EFFECTS**
  - ▶ **Uncommon** Cough · drowsiness · increased risk of infection
  - ▶ **Rare or very rare** Abdominal pain · conjunctivitis · Kawasaki disease · seizure · stroke · thrombocytopenia · vasculitis
- **CONCEPTION AND CONTRACEPTION** Avoid pregnancy for 3 months after vaccination.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

#### **Powder and solvent for suspension for injection**

EXCIPIENTS: May contain Gelatin, neomycin

- ▶ **Varivax** (Merck Sharp & Dohme Ltd)  
Varivax vaccine powder and solvent for suspension for injection 0.5ml vials | 1 vial [PoM] £30.28

#### **Powder and solvent for solution for injection**

EXCIPIENTS: May contain Neomycin

- ▶ **Varilrix** (GlaxoSmithKline UK Ltd)  
Varilrix vaccine powder and solvent for solution for injection 0.5ml vials | 1 vial [PoM] £27.31

F 814

22-May-2019

## Yellow fever vaccine, live

### ● INDICATIONS AND DOSE

#### **Immunisation against yellow fever**

- ▶ BY DEEP SUBCUTANEOUS INJECTION
- ▶ Child 6–8 months (administered on expert advice): Infants under 9 months should be vaccinated only if the risk of yellow fever is high and unavoidable (consult product literature or local protocols)
- ▶ Child 9 months–17 years: 0.5 mL for 1 dose

### IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: YELLOW FEVER VACCINE (STAMARIL<sup>®</sup>) AND FATAL ADVERSE REACTIONS: EXTREME CAUTION NEEDED IN PEOPLE WHO MAY BE IMMUNOSUPPRESSED (APRIL 2019)

The yellow fever vaccine (Stamaril<sup>®</sup>) has been associated with an increased risk of life-threatening reactions and must not be given to patients with a history of thymus dysfunction (including myasthenia gravis and thymoma), to patients that are immunosuppressed, or that have had a thymectomy. Prior to administering yellow fever vaccines, healthcare professionals are advised to familiarise themselves with any contraindications and special precautions, and to defer vaccination if it is suspected that a patient is immunosuppressed, until specialist advice can be sought.

Healthcare professionals administering vaccines should consult information in the YF Vaccine Centre code of practice and strengthen protocols and checklists to avoid inappropriate administration.

- **CONTRA-INDICATIONS** Children under 6 months · history of thymus dysfunction

### ● CAUTIONS

#### **CAUTIONS, FURTHER INFORMATION**

- ▶ Administration with MMR vaccine Yellow fever and MMR vaccines should not be administered on the same day; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.
- **INTERACTIONS** → Appendix 1: live vaccines
- **SIDE-EFFECTS**
  - ▶ **Common or very common** Asthenia · crying · drowsiness
  - ▶ **Uncommon** Abdominal pain
  - ▶ **Rare or very rare** Rhinitis · yellow fever vaccine-associated neurotropic disease · yellow fever vaccine-associated viscerotropic disease
  - ▶ **Frequency not known** Angioedema · influenza like illness · paraesthesia

**SIDE-EFFECTS, FURTHER INFORMATION** Very rare vaccine-associated adverse effects may occur, such as viscerotropic disease (yellow-fever vaccine-associated viscerotropic disease, YEL-AVD), a syndrome which may include metabolic acidosis, muscle and liver cirrhosis, and multi-organ failure. Neurological disorders (yellow fever vaccine-associated neurotropic disease, YEL-AND) such as encephalitis have also been reported. These very rare adverse effects usually occur after the first dose of yellow fever vaccine in those with no previous immunity. Increased risk of fatal reactions reported in patients aged 60 years and older and those who are immunosuppressed.

- **ALLERGY AND CROSS-SENSITIVITY** Yellow fever vaccine should only be considered under the guidance of a specialist in individuals with evidence of previous anaphylactic reaction to egg.
- **PREGNANCY** Live yellow fever vaccine should not be given during pregnancy because there is a theoretical risk of fetal infection. Pregnant women should be advised not to travel to areas at high risk of yellow fever. If exposure cannot be avoided during pregnancy, then the vaccine should be given if the risk from disease in the mother outweighs the risk to the fetus from vaccination.
- **BREAST FEEDING** Avoid; seek specialist advice if exposure to virus cannot be avoided.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

#### **Powder and solvent for suspension for injection**

- ▶ **Stamaril** (Sanofi Pasteur)  
Stamaril vaccine powder and solvent for suspension for injection 0.5ml vials | 1 vial [PoM] £39.72